<DOC>
	<DOCNO>NCT02784444</DOCNO>
	<brief_summary>This randomize , double-blinded study three dose MSDC-0602K ( 62.5 , 125 250 mg ) placebo give orally daily subject biopsy proven NASH fibrosis cirrhosis . Subjects stratify presence T2DM ( Yes/No ) , use Vitamin E ≥ 400 IU ( Yes/No ) fibrosis score ( 1 ≥ 2 ) ensure equal representation across group . The primary efficacy endpoint , hepatic histological improvement NAS define decrease least 2 point concurrent worsen fibrosis stage , assess 12 month . Visits clinic baseline , 1 , 2 , 3 , 6 , 9 , 12 month , one 2- week follow-up visit .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability &amp; Efficacy MSDC 0602K Patients With NASH</brief_title>
	<detailed_description>This randomize , double-blinded study three dose MSDC-0602K ( 62.5 , 125 250 mg ) placebo give orally daily subject biopsy proven NASH fibrosis cirrhosis . Subjects stratify presence T2DM ( Yes/No ) , use Vitamin E ≥ 400 IU ( Yes/No ) fibrosis score ( 1 ≥ 2 ) ensure equal representation across group . The primary efficacy endpoint , well 5 secondary endpoint , assess 12 month . Visits clinic baseline , 1 , 2 , 3 , 6 , 9 , 12 month , one 2- week follow-up visit . Subjects biopsy proven NASH ( NAS ≥ 4 ; least one point category ) F1 F3 fibrosis score enrol study . Subjects demonstrate cirrhosis , hepatitis C , excess alcohol consumption exclude trial . Females postmenopausal surgically sterilize . Patients must sign informed consent . Approximately 200 subject randomize intent 180 subject complete 12 month assessment ( 4 group ; approximately 45 subjects/group ) 37 site US . Subjects complete study replace . Size # 00 opaque gelatin capsule prepare use MSDC-0602K tablet match placebo capsule contain micro-crystalline cellulose . All dose take orally 8 ounce ( one glassful ) room temperature water least 30 minute breakfast . Dose level MSDC-0602K 62.5mg , 125 mg , 250 mg. Each patient self-administer one capsule per day . This study comprise maximum 21-day Screening period , treatment period 360 day 14-day follow-up period . The total duration study patient approximately 402 day , include follow-up . Safety assess periodic measurement vital sign , 12 lead electrocardiogram ( ECG ) , physical examination question regard potential adverse event ( AEs ) . Fasting blood sample clinical chemistry hematology collect study visit ( Screening Study Visits 1-8 ) . Samples urinalysis collect Screening Study Visits except Visits 2 3 ( Days 1 , 90 , 180 , 270 360 ) . Blood sample trough PK analysis MSDC-0602 MSDC 0597 ( hydroxymetabolite ) take Study Visits 2 , 4 , 5 , 6 7 ( Days 30 , 90 , 180 , 270 360 ) .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Adult subject age 1875 year , inclusive . Histological evidence NASH , base biopsy , NAS ( NASH CRN score ) ≥ 4 score least 1 component NAS . Histological evidence liver fibrosis define NASH CRN System Stage 1 3 . Male female subject NASH fibrosis score F1 F3 ( NASH CRN score ) interpretable liver biopsy within 6 month prior start study . If usable liver biopsy available within 6 month prior start study , subject must agree liver biopsy perform Screening eligible subject meet entry criterion . All eligible subject must agree one liver biopsy end study treatment ( one year ) . If subject type 2 diabetes , must stable reasonable control . Male female subject reasonably control type 2 diabetes mellitus ( DM ) define physician 's care diabetes glycosylated hemoglobin [ HbA1c ] ≤ 9.5 % . If subject take permitted antidiabetic therapy , must stable dos follow antidiabetic period least 3 month prior diagnostic liver biopsy : metformin , GLP1 agonists , SGLT2 inhibitor , sulfonylurea , DPP4 inhibitor . Refer Section 4.3 additional clarification use antidiabetic . Male female subject take Vitamin E stable dose Vitamin E ( ≥ 400 IU ) period least 3 month prior diagnostic liver biopsy . Females either postmenopausal ( least 12 month since last menses ) surgically sterilize ( bilateral tubal ligation hysterectomy ) . Menopausal status verify folliclestimulating hormone ( FSH ) test . If FSH level 40 mIU/mL , method birth control must use . Those bilateral tubal ligation must also use barrier method birth control . In addition , female must negative pregnancy test Screening Day 1 regardless childbearing potential . For postmenopausal woman , FSH level 40 mIU/mL serum pregnancy result indeterminant , subject assess pregnant . Males female partner childbearing potential must agree use adequate contraceptive method ( include condom , plus one form contraception ) engage sexual intercourse . Body Mass Index ( BMI ) &lt; 45 kg/m2 . Willing able sign inform consent document indicate understand purpose procedure require study willingness participate study . Willing able make Screening visit clinic eight visit 12.5 month period . Known history HIV . Prior liver transplantation . Other welldocumented cause active chronic liver disease , include , restrict : history positive hepatitis B surface antigen ( HBsAg ) HCV RNA , suspicion druginduced liver disease , alcoholic liver disease autoimmune hepatitis , Wilson 's disease hemochromatosis , primary biliary cirrhosis , primary sclerosing cholangitis , genetic hemochromatosis , know suspected HCC , history plan liver transplant current MELD score &gt; 12 . Subjects need viremia free 2 year . History cirrhosis and/or hepatic decompensation include ascites , hepatic encephalopathy variceal bleeding . Platelet count &lt; 100,000/µL blood . AST ALT &gt; 160 U/L . Bilirubin &gt; 1.8 mg/dL and/or serum albumin &lt; 2.5 gms/dL . Impaired coagulation PT/INR ≥ 1.5 time ULN . History alcohol abuse drug abuse within 6 month Screening . Inability safely obtain liver biopsy . Type 1 diabetes mellitus . Use ursodeoxycholic acid . Use diabetes medication metformin , GLP1 agonists , SGLT2 inhibitor , sulfonylurea , DPP4 inhibitor three month prior baseline diagnostic liver biopsy study unless specify protocol . Use insulin PPARγ agonist ( pioglitazone rosiglitazone ) allow . Refer Section 4.3 additional clarification use antidiabetic . Use concomitant medication know significant metabolism CYP2C8 CPY2C9 include : paclitaxel , phenytoin , warfarin , celecoxib , tolbutamide , replaglinide . History diabetic ketoacidosis hyperosmolar nonketotic coma . History heart failure ( include CHF ) previous cardiovascular event ( myocardial infarct , bypass surgery , PTCA ) within past 6 month prior Screening . Serum creatinine &gt; 2 mg/dL . Current recurrent disease may affect action , absorption disposition study treatment , clinical laboratory assessment . Current history severe unstable disorder ( medical psychiatric ) require treatment may make patient unlikely complete study . Blood pressure great 160/100 mmHg . Patients elevate BP ( &lt; 160/100 mmHg ) without current treatment allow discretion Investigator primary care physician . Individuals hypertension must stabilize current treatment regimen least 6 week prior Screening . Known suspect intolerance hypersensitivity study drug , closely related compound state ingredient . Have participate investigational study receive investigational drug within 30 day 5 halflives ( whichever longer ) prior study drug administration . Blood donation 1 pint within 56 day Screening . Plasmapheresis plasma donation within 30 day Screening . Single 12lead ECG demonstrate QTcB &gt; 450 msec Screening . A single repeat ECG may do Investigator 's discretion . Any surgical medical condition may significantly alter absorption drug substance include , limited , follow : history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection , gastric bypass , gastric stapling , gastric banding , currently active inflammatory bowel syndrome . Evidence clinically relevant pathology could interfere study result put patient 's safety risk . Malignancy , include leukemia lymphoma ( include basal cell skin cancer ) treat within last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NASH</keyword>
</DOC>